263 related articles for article (PubMed ID: 21181310)
1. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.
Troll JG
Curr Atheroscler Rep; 2011 Feb; 13(1):51-6. PubMed ID: 21181310
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N
BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863
[TBL] [Abstract][Full Text] [Related]
3. Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.
Bednasz C; Luque AE; Zingman BS; Fischl MA; Gripshover BM; Venuto CS; Gu J; Feng Z; DiFrancesco R; Morse GD; Ma Q
Curr Vasc Pharmacol; 2016; 14(3):280-7. PubMed ID: 26733388
[TBL] [Abstract][Full Text] [Related]
4. Statins and renal disease: friend or foe?
Deshmukh A; Mehta JL
Curr Atheroscler Rep; 2011 Feb; 13(1):57-63. PubMed ID: 21053107
[TBL] [Abstract][Full Text] [Related]
5. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
6. The role of statins in the setting of HIV infection.
Eckard AR; McComsey GA
Curr HIV/AIDS Rep; 2015 Sep; 12(3):305-12. PubMed ID: 26126687
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.
Willig AL; Overton ET
Curr HIV/AIDS Rep; 2016 Oct; 13(5):289-96. PubMed ID: 27541600
[TBL] [Abstract][Full Text] [Related]
8. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update.
Zanetti HR; Roever L; Gonçalves A; Resende ES
Curr Atheroscler Rep; 2018 Feb; 20(2):9. PubMed ID: 29423787
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy with heart.
Randell P; Moyle G
Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
[TBL] [Abstract][Full Text] [Related]
10. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
Ahmed MH; Al-Atta A; Hamad MA
Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
[TBL] [Abstract][Full Text] [Related]
11. [Cardiovascular risk in HIV infected patients].
Raimundo P; Miranda A; Ribeiro J; Mansinho K
Acta Med Port; 2010; 23(4):669-76. PubMed ID: 20687996
[TBL] [Abstract][Full Text] [Related]
12. [Lipid disorders in patients with HIV-induced diseases].
Chanu B; Valensi P
Presse Med; 2005 Sep; 34(15):1087-94. PubMed ID: 16334888
[TBL] [Abstract][Full Text] [Related]
13. Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects.
Dubé MP; Shen C; Mather KJ; Waltz J; Greenwald M; Gupta SK
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):847-54. PubMed ID: 20673142
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'.
Balasubramanyam A; Sekhar RV; Jahoor F; Jones PH; Pownall HJ
Curr Opin Lipidol; 2004 Feb; 15(1):59-67. PubMed ID: 15166810
[TBL] [Abstract][Full Text] [Related]
15. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
Crook M
Ann Clin Biochem; 2007 May; 44(Pt 3):219-31. PubMed ID: 17456292
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.
Anuurad E; Semrad A; Berglund L
Metab Syndr Relat Disord; 2009 Oct; 7(5):401-10. PubMed ID: 19355810
[TBL] [Abstract][Full Text] [Related]
17. [Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].
Polo R; José Galindo M; Martínez E; Alvarez J; Arévalo JM; Asensi V; Cánoves D; Cáncer E; Collazos J; Estrada V; Gómez-Candela C; Johnston S; Locutura J; López-Aldeguer J; Lozano F; Miralles C; Muñoz-Sanz A; Ortega E; Pascua J; Pedrol E; Pulido F; San Martín M; Sanz J; Viciana P; Chamorro L;
Enferm Infecc Microbiol Clin; 2006 Feb; 24(2):96-117. PubMed ID: 16545318
[TBL] [Abstract][Full Text] [Related]
18. Lipid metabolism in treated HIV Infection.
Dubé MP; Cadden JJ
Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risks of antiretroviral therapies.
Mondy K; Tebas P
Annu Rev Med; 2007; 58():141-55. PubMed ID: 17217329
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors.
Boccara F
AIDS; 2008 Sep; 22 Suppl 3():S19-26. PubMed ID: 18845918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
